Genes associated with intestinal permeability in ulcerative colitis: Changes in expression following infliximab therapy

Inflammatory Bowel Diseases

Volumn 18, Issue 8, 2012, Pages 1399-1410

  Toedter, Gary ^a   Li, Katherine ^a   Sague, Sarah ^a   Ma, Keying ^a   Marano, Colleen ^b   MacOritto, Michael ^c   Park, Jennifer ^c   Deehan, Renée ^c   Matthews, Andrea ^c   Wu, Gary D ^d   Lewis, James D ^d   Arijs, Ingrid ^e   Rutgeerts, Paul ^e   Baribaud, Frédéric ^a  

^a CENTOCOR INC   (United States)

^b Clinical Research and Development Inc   (United States)

^c Selventa   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

epithelial mesenchymal transition; infliximab; tight junction; ulcerative colitis

Indexed keywords

INFLIXIMAB; MESSENGER RNA;

ADULT; ARTICLE; CAUSAL MODELING; COLON BIOPSY; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; HUMAN; INTESTINE MUCOSA PERMEABILITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, MONOCLONAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CELL MEMBRANE PERMEABILITY; COLITIS, ULCERATIVE; DRUG RESISTANCE; FEMALE; GASTROINTESTINAL AGENTS; GENE EXPRESSION PROFILING; HUMANS; INTESTINES; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84859720700     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22853     Document Type: Article

References (39)

1. Baumgart DC, Carding SR,. Inflammatory bowel disease: cause and immunobiology. Lancet. 2007; 369: 1627-1640.
2. Schirbel A, Fiocchi C,. Inflammatory bowel disease: established and evolving considerations on its etiopathogenesis and therapy. J Dig Dis. 2010; 11: 266-276.
3. Mankertz J, Schulzke JD,. Altered permeability in inflammatory bowel disease: pathophysiology and clinical implications. Curr Opin Gastroenterol. 2007; 23: 379-383.
4. Schmitz H, Barmeyer C, Fromm M, et al. Altered tight junction structure contributes to the impaired epithelial barrier function in ulcerative colitis. Gastroenterology. 1999; 116: 301-309.
5. Rieder F, Fiocchi C,. Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Curr Opin Gastroenterol. 2008; 24: 462-468.
6. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005; 353: 2462-2476.
7. Lichtenstein GR, Rutgeerts P,. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010; 16: 338-346.
8. Scallon B, Cai A, Solowski N, et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther. 2002: 301: 418-426.
9. ten Hove T, van Montfrans C, Peppelenbosch MP, et al. Infliximab treatment induces apoptosis of lamina propria T lymphocytes in Crohn's disease. Gut. 2002; 50: 206-211.
10. van Deventer SJ,. Review article: targeting TNFα as a key cytokine in the inflammatory processes of Crohn's diseasethe mechanisms of action of infliximab. Aliment Pharmacol Ther. 1999; 13: 3-8.
11. Toedter G, Li K, Marano C, et al. Gene expression profiling and response signatures associated with differential responses to infliximab treatment in ulcerative colitis. Am J Gastroenterol. 2011; 106: 1272-1280.
12. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol. 2002; 97: 2000-2004.
13. Dudoit S, Gentleman RC, Quackenbush J,. Open source software for the analysis of microarray data. Biotechniques. 2003;(Suppl): 45-51.
14. Smith JJ, Kenney RD, Gagne DJ, et al. Small molecule activators of SIRT1 replicate signaling pathways triggered by calorie restriction in vivo. BMC Sys Biol. 2009; 3: 31.
15. Kumar R, Blakemore SJ, Ellis CE, et al. Causal reasoning identifies mechanisms of sensitivity for a novel AKT kinase inhibitor, GSK690693. BMC Genomics. 2010; 11: 419.
16. Schulzke JD, Ploeger S, Amasheh M, et al. Epithelial tight junctions in intestinal inflammation. Ann N Y Acad Sci. 2009; 1165: 294-300.
17. Laukoetter MG, Nava P, Nusrat A,. Role of the intestinal barrier in inflammatory bowel disease. World J Gastroenterol. 2008; 14: 401-407.
18. Clayburgh DR, Shen L, Turner JR,. A porous defense: the leaky epithelial barrier in intestinal disease. Lab Invest. 2004; 84: 282-291.
19. Sandborn WJ, Feagan BG, Fedorak RN, et al. A randomized trial of Ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn's disease. Gastroenterology. 2008; 135: 1130-1141.
20. Maharshak N, Plevy SE,. A Crohn's disease patient who does not respond to infliximab: what is next? Clin Gastroenterol Hepatol. 2011 [Epub ahead of print].
21. Amasheh S, Meiri N, Gitter AH, et al. Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci. 2002; 115: 4969-4976.
22. Weber CR, Nalle SC, Tretiakova M, et al. Claudin-1 and claudin-2 expression are elevated in inflammatory bowel disease and may contribute to early neoplastic transformation Lab Invest. 2008; 88: 1110-1120.
23. Zeissig S, Burgel N, Gunzel D, et al. Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut. 2007; 56: 61-72.
24. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88: 277-285.
25. Sandor Z, Deng XM, Khomenko T, et al. Altered angiogenic balance in ulcerative colitis: a key to impaired healing? Biochem Biophys Res Commun. 2006; 350: 147-150.
26. Wang YD, Tan XY, Zhang K,. Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Inflamm. 2009; 2009: 275072.
27. von Lampe B, Barthel B, Coupland SE, et al. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 2000; 47: 63-73.
28. Wang FQ, So J, Reierstad S, et al. Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by activation of progelatinase. Int J Cancer. 2005; 114: 19-31.
29. von Bredow DC, Cress AE, Howard EW, et al. Activation of gelatinase-tissue-inhibitors-of-metalloproteinase complexes by matrilysin. Biochem J. 1998; 331 (Pt 3): 965-972.
30. Salmela MT, Pender SL, Karjalainen-Lindsberg ML, et al. Collagenase-1 (MMP-1), matrilysin-1 (MMP-7), and stromelysin-2 (MMP-10) are expressed by migrating enterocytes during intestinal wound healing. Scand J Gastroenterol. 2004; 39: 1095-1104.
31. Matsuno K, Adachi Y, Yamamoto H, et al. The expression of matrix metalloproteinase matrilysin indicates the degree of inflammation in ulcerative colitis. J Gastroenterol. 2003; 38: 348-354.
32. Lohi J, Wilson CL, Roby JD, et al. Epilysin, a novel human matrix metalloproteinase (MMP-28) expressed in testis and keratinocytes and in response to injury. J Biol Chem. 2001; 276: 10134-10144.
33. Saarialho-Kere U, Kerkela E, Jahkola T, et al. Epilysin (MMP-28) expression is associated with cell proliferation during epithelial repair. J Invest Dermatol. 2002; 119: 14-21.
34. Illman SA, Lohi J, Keski-Oja J,. Epilysin (MMP-28) structure, expression and potential functions. Exp Dermatol. 2008; 17: 897-907.
35. Niesner U, Albrecht I, Janke M, et al. Autoregulation of Th1-mediated inflammation by twist1. J Exp Med. 2008; 205: 1889-1901.
36. Ye D, Ma I, Ma TY,. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol. 2006; 290: G496-G504.
37. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005; 129: 550-564.
38. Madara JL, Stafford J,. Interferon-γ directly affects barrier function of cultured intestinal epithelial monolayers. J Clin Invest. 1989; 83: 724-727.
39. Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomized trial. Lancet. 2002; 359: 1541-1549.